Teva Pharmaceutical Industries Limited’s TEVA shares have risen 21.6% in three months. Over the past few quarters, Teva has successfully launched several biosimilars and other high-value, complex ...

ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, and contract manufacturing. Despite cash burn concerns, ANI's revenue ...

Generic drugmakers continue to navigate a challenging U.S. market defined by persistent price erosion, intense competition and structurally thin margins. While demand for generics remains steady, ...

Access to innovative medicines remains a critical issue in healthcare. Teva Pharmaceuticals is tackling this challenge head-on, driving scientific innovation to deliver high-quality medicines that ...

Granules India gets USFDA nod for ADHD drug with 180-day exclusivity. The US market size for the ADHD drug is estimated at $41 million. Granules aims to build a differentiated portfolio of complex ...

Glycerol phenylbutyrate oral liquid is indicated for the chronic management of patients with urea cycle disorders. Sims added, "It expands access for patients and providers, and reinforces our ...

Generic drugmakers continue to face mounting pressure not only from pricing competition but also from Trump’s push for pharmaceutical import tariffs and the proposed “most-favored-nation” pricing ...